Gan & Lee Pharmaceuticals.: history, ownership, mission, how it works & makes money

From its founding in 1998 to pioneering China's first insulin analogs-Prandilin® (Lispro) and Basalin® (Glargine)-Gan & Lee Pharmaceuticals has evolved into a vertically integrated biotech powerhouse (listed as 603087.SH) that built the world's third-largest recombinant human insulin production base by 2005 and expanded globally with a New Jersey subsidiary in 2014, FDA approval of GanleeFine® in 2020 and EMA GMP clearance in 2024; today the company markets 10 commercial products across 19 countries (registered in 23), recorded domestic Q1 2025 sales of RMB 889 million (up 80.07% year-on-year) and international sales of RMB 95 million (up 45.21%), secured all six insulin bids in China's 2024 centralized procurement, and has entered a strategic cooperation with Hillhouse Capital (Nov 2025) to reposition assets and sharpen focus on innovative metabolic drug development while monetizing franchise services, partnerships and device lines that underpin its revenue model and global expansion ambitions.

Gan & Lee Pharmaceuticals. (603087.SS) - Intro

• Founded in 1998; developed China's first domestic insulin analog Prandilin® (Lispro), establishing an early lead in biopharmaceutical diabetes care.
• 2002: Launched Basalin® (Glargine), China's first long‑acting human insulin analog, expanding the company's chronic care portfolio.
• 2005: Completed a recombinant human insulin production base - at the time the world's third‑largest facility of its kind.
• 2014: Established a U.S. subsidiary in New Jersey to support regulatory, R&D and commercial expansion in North America.
• 2020: GanleeFine® disposable pen needle received U.S. FDA approval, marking a major milestone in international market access.
• 2024: EMA granted GMP inspection approval for GanleeFine®, enhancing EU market competitiveness and export potential.

• Listed on the Shanghai Stock Exchange: ticker 603087.SS.
• Shareholder mix: combination of institutional investors, domestic strategic shareholders (founders/management related holdings and biotech conglomerates) and retail shareholders typical of large Chinese mid‑caps.
• Corporate entities include the Shanghai headquarters, the New Jersey subsidiary (established 2014), production subsidiaries for insulin and device manufacturing, and dedicated R&D units.

• Mission: develop accessible, high‑quality diabetes treatments and delivery devices to improve patient outcomes.
• Vision: be a global leader in insulin and diabetes care technologies while expanding international reach through regulatory approvals and strategic partnerships.
• Core values: patient‑centric innovation, quality and compliance, global collaboration.

• R&D: combination of in‑house biologics development (insulin analogs, formulations) and device engineering (pen needles, delivery systems); clinical trials follow international regulatory pathways (NMPA, FDA, EMA).
• Manufacturing: vertically integrated production - recombinant insulin bulk manufacture, formulation, filling, and device assembly concentrated in high‑capacity facilities built since 2005.
• Regulatory pathway: domestic approvals through China's NMPA and targeted international approvals (FDA 2020 for GanleeFine®, EMA GMP inspection approval 2024) to enable exports and local registrations in multiple markets.
• Commercialization: direct sales and distribution in China via hospital and retail pharmacy channels, plus export and partnerships for international distribution; device sales complement pharmaceutical product revenues.

• Product sales: primary revenue from insulin analogs (Prandilin®, Basalin®) and insulin delivery disposables (GanleeFine® pen needles).
• Geographic mix: majority revenue historically from China, with growing contributions from exports and overseas subsidiaries following FDA and EMA approvals.
• Complementary income: licensing, contract manufacturing and potential co‑development partnerships with international pharma/device firms.

• Prandilin® (Lispro) - domestic insulin analog, marketed in China.
• Basalin® (Glargine) - long‑acting insulin analog, marketed in China and subject to international registration efforts.
• GanleeFine® - disposable pen needle; FDA approval (2020) and EMA GMP inspection approval (2024) enable expansion into U.S., EU and other regulated markets.

Gan & Lee Pharmaceuticals. (603087.SS): History

• Listing: Shanghai Stock Exchange (603087.SH) - commitment to transparency and shareholder value.
• Strategic pivot: from broad pharma & manufacturing to core innovative drug development in metabolic disease.
• Major 2025 corporate action: strategic cooperation with Hillhouse Capital (Nov 2025) transferring controlling stake in GanGan Medical Technology Jiangsu Co., Ltd., while retaining a minority stake.

• Public shareholders: majority of tradable free float on SSE under 603087.SH.
• Post-November 2025 arrangement:
  • Gan & Lee transferred controlling stake in GanGan Medical Technology Jiangsu to Hillhouse Capital.
  • Gan & Lee retained a minority stake (strategic focus + value sharing model) to capture upside while focusing resources on innovative drug R&D.
• Purpose of transfer: unlock asset value, accelerate organizational upgrades at GanGan Jiangsu, strengthen R&D collaboration and global customer reach via Hillhouse's platform.

• Mission: Become a world-class pharmaceutical company by concentrating on innovative drugs targeting metabolic diseases (diabetes and obesity).
• Strategy: concentrate internal capital and talent on novel biologics/peptide/metabolic programs while leveraging partnerships (e.g., Hillhouse) to optimize non-core asset value and operational efficiency.

• Operational: accelerate organizational upgrades at GanGan Jiangsu and unlock scale efficiencies.
• R&D & commercial: strengthen R&D innovation and extend global customer networks for GanGan Jiangsu, while Gan & Lee concentrates on metabolic drug pipelines.
• Financial: optimized resource allocation, asset value realization through a "strategic focus + value sharing" structure to support long-term growth.

Gan & Lee Pharmaceuticals. (603087.SS): Ownership Structure

• Mission and Values: Provide high-quality medicines and services to improve global patient outcomes.
• Vision: Expand internationally and attain leading pharmaceutical-company status.
• Core values: Science & Excellence; Quality First, Innovation Forever; advanced production standards and patient-focused service.
• Culture/Tenet: Scientific leadership, R&D-driven growth, and operational excellence guide product development and market expansion.

• Business model: R&D → regulatory approval → manufacture (API & finished dosage forms) → domestic & export sales (hospitals, distributors, retail/OTC) → licensing and partnerships for international commercialization.
• Revenue drivers: proprietary drugs, generic injectable portfolio, vaccine/oncology biologics collaborations, contract manufacturing and outbound licensing.
• Margins: R&D investment reduces short-term margins but supports higher-value patented products and specialty injectables with premium pricing.

Gan & Lee Pharmaceuticals. (603087.SS): Mission and Values

• Vertically integrated model: R&D → GMP manufacturing → commercialization for insulin analogs, devices and related consumables.
• Integrated quality & regulatory system: quality management and regulatory compliance aligned to international standards (GMP, ISO-related practices and country-specific registration dossiers) to ensure safety and efficacy.
• Manufacturing footprint: operates a recombinant human insulin production base and a dedicated disposable pen needle production line, both maintained to GMP standards to support scale, traceability and product consistency.
• Global market strategy: products launched in 19 countries and registered in 23 countries, combining direct exports and partner-led commercialization.
• Strategic alliances: collaborates with international partners (for example, alliance activity with Sandoz) to enter developed markets and leverage global distribution channels.
• R&D pipeline focus: new chemical entities and biologics targeting metabolic diseases (diabetes), cardiovascular disease and other therapeutic areas, with both device-drug combination development and standalone therapeutic candidates.

• Product sales: primary revenue from insulin analogs (vials, cartridges) and disposable pen needles sold domestically and internationally.
• Device consumables: recurring revenue from high-margin pen needle consumables and ancillary devices that drive repeat purchases.
• Partnered commercialization: licensing, co-promotion and distribution deals (e.g., with Sandoz) provide milestone payments, shared revenues and access to developed-market channels.
• R&D and contract manufacturing: fees from contract manufacturing or technical transfers and potential milestone/license income from out-licensing pipeline assets.

• Pipeline breadth: combination of biosimilars/insulin analog improvements, new biologic candidates for metabolic and cardiovascular indications, and next-generation delivery devices.
• Cost structure: R&D investment concentrated on biologics scale-up and device engineering; typical development timelines for biologics extend multiple years with staged milestone spending.
• Value creation: commercialization of improved insulin analogs and device combos can increase price realization and patient adherence, driving lifetime customer value in diabetes care.

• Publicly listed on the Shanghai Stock Exchange (603087.SS) with institutional and retail shareholders.
• Major shareholders include founding/management-related entities and strategic investors; board and executive leadership emphasize manufacturing quality, regulatory compliance and international expansion.

• Quality systems in place to meet GMP and international registration requirements for biologics and medical devices, supporting registrations across 23 countries.
• Regulatory strategy combines domestic approvals with CE/partner-facilitated pathways and dossier submissions for developed-market registrations via collaborators.

Gan & Lee Pharmaceuticals. (603087.SS) - How It Works

• Core activities: discovery and development of insulin analogs, formulation and device integration (pre-filled pens, pumps), clinical trials, regulatory filings and commercial distribution.
• Manufacturing footprint: GMP-capable sterile drug substance and drug product lines for rapid scale-up to meet centralized procurement volumes.
• Commercial model: direct sales in China, selected distributors and partners overseas, plus technology-transfer and supply agreements (franchise services) with regional manufacturers.
• Strategic partnerships: capital and resource alignment with private equity (notably Hillhouse Capital) to optimize production, global registration and market access.

• Product sales: Primary revenue from insulin analogs (branded and biosimilar formulations) and connected delivery devices sold directly in China and through export channels.
• Procurement wins: In 2024 Gan & Lee secured all six of its insulin products in China's National Insulin-Specific Centralized Procurement, locking in large-volume, price-negotiated contracts that underpin recurring domestic sales.
• International expansion: Growing export sales (RMB 95 million in Q1 2025, +45.21% YoY) from registrations and distributor agreements in Asia, Latin America and select emerging markets.
• Franchise services: Revenue from licensing, technology transfer, contract manufacturing and supply agreements with regional partners, enabling low-capital market entry and ongoing royalty/licensing income.
• Value capture via devices: Integrated pen and device offerings increase stickiness, enabling higher ASPs (average selling prices) and cross-selling opportunities.
• Operational leverage: Scale from procurement wins and manufacturing capacity improves gross margins as volumes rise.

• Q1 2025 domestic sales: RMB 889 million (+80.07% YoY), driven by insulin product uptake post-procurement win.
• Q1 2025 international sales: RMB 95 million (+45.21% YoY), reflecting accelerated global registrations and exports.
• 2024 procurement: Won bidding for all six insulin products in China's national insulin procurement program - a major demand guarantee.
• Hillhouse Capital partnership: Expected to optimize resource allocation, finance capacity expansion and enable new cooperation (M&A, global go-to-market), potentially unlocking additional revenue streams.

Gan & Lee Pharmaceuticals (603087.SS): How It Makes Money

• Core revenue streams: commercial insulin sales (domestic hospital and retail tenders), exports to international markets, licensing and collaboration revenues, and contract manufacturing for third parties.
• Product breadth: 10 commercial products sold across 19 countries, providing diversified geographic and channel exposure.
• Procurement strength: ranked first in 2024 National Insulin-Specific Centralized Procurement for insulin analog demand - a dominant position in China's largest buyer-driven market.
• Regulatory & market expansion: FDA approval of GanleeFine® (2020) and EMA GMP inspection approval (2024) unlock higher-margin developed-market sales and facilitate partnerships with global distributors.
• Capital & strategic support: cooperation with Hillhouse Capital aimed at accelerating organizational upgrades, boosting R&D innovation, and expanding the global customer network to drive long-term top-line growth.
• Therapeutic focus: emphasis on diabetes and obesity metabolic drugs aligns with global demand trends, supporting sustained market opportunity and pipeline-driven future revenues.